Bjoern B. Burckhardt

Muenster, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Bradykinin contributes to vasogenic edema in murine experimental cerebral malaria.

Bradykinin contributes to vasogenic edema in murine experimental cerebral malaria.

Journal: The Journal of clinical investigation

Published: July 14, 2026

ABSTRACTS OF THE JOINT INTERNATIONAL SYMPOSIA "VITAMIN D IN PREVENTION AND THERAPY" AND "BIOLOGIC EFFECTS OF LIGHT".

ABSTRACTS OF THE JOINT INTERNATIONAL SYMPOSIA "VITAMIN D IN PREVENTION AND THERAPY" AND "BIOLOGIC EFFECTS OF LIGHT".

Journal: Anticancer research

Published: May 27, 2026

Bradykinin Contributes to Vasogenic Edema in Murine Experimental Cerebral Malaria.

Bradykinin Contributes to Vasogenic Edema in Murine Experimental Cerebral Malaria.

Journal: bioRxiv : the preprint server for biology

Published: May 13, 2026

Reverse Fosmidomycin Analogs as Bisubstrate Inhibitors: Binding Mode Elucidation and Mechanistic Insights.

Reverse Fosmidomycin Analogs as Bisubstrate Inhibitors: Binding Mode Elucidation and Mechanistic Insights.

Journal: Journal of medicinal chemistry

Published: May 06, 2026

Broadening the View: Substance P and Its Metabolism in Pruritus-Related Diseases.

Broadening the View: Substance P and Its Metabolism in Pruritus-Related Diseases.

Journal: The Journal of dermatology

Published: January 30, 2026

Bradykinin contributes to vasogenic edema in murine experimental cerebral malaria.

Bradykinin contributes to vasogenic edema in murine experimental cerebral malaria.

Journal: The Journal of clinical investigation

Published: November 24, 2025

Integrative preclinical strategy for pharmacokinetic profiling and candidate selection of 3-hydroxypropanamidines: a promising antimalarial class.

Integrative preclinical strategy for pharmacokinetic profiling and candidate selection of 3-hydroxypropanamidines: a promising antimalarial class.

Journal: Malaria journal

Published: October 26, 2025

Structure-Activity Relationships of 3-Hydroxypropanamidines (HPAs) with Potent In Vivo Antimalarial Activity.

Structure-Activity Relationships of 3-Hydroxypropanamidines (HPAs) with Potent In Vivo Antimalarial Activity.

Journal: Journal of medicinal chemistry

Published: September 08, 2025

Angiotensin II/Angiotensin I Ratio as a New Pharmacodynamic Parameter for Population Modelling in Healthy Adults and Children with Heart Failure Treated with Enalapril.

Angiotensin II/Angiotensin I Ratio as a New Pharmacodynamic Parameter for Population Modelling in Healthy Adults and Children with Heart Failure Treated with Enalapril.

Journal: Pharmaceutics

Published: August 31, 2025

Development and Characterization of the First Selective Class IIb Histone Deacetylase Degraders.

Development and Characterization of the First Selective Class IIb Histone Deacetylase Degraders.

Journal: Journal of medicinal chemistry

Published: June 18, 2025

TKK130 is a 3-Hydroxy-Propanamidine (HPA) with Potent Antimalarial In Vivo Activity and a High Barrier to Resistance.

TKK130 is a 3-Hydroxy-Propanamidine (HPA) with Potent Antimalarial In Vivo Activity and a High Barrier to Resistance.

Journal: Journal of medicinal chemistry

Published: December 26, 2024

Deciphering the Therapeutic Potential of Novel Pentyloxyamide-Based Class I, IIb HDAC Inhibitors against Therapy-Resistant Leukemia.

Deciphering the Therapeutic Potential of Novel Pentyloxyamide-Based Class I, IIb HDAC Inhibitors against Therapy-Resistant Leukemia.

Journal: Journal of medicinal chemistry

Published: November 27, 2024

Showing 1-12 of 67

Last Updated: 09/26/2026